Literature DB >> 7511068

Evaluation of the therapeutic effect of TAE on primary liver cancer.

T Yamada1, F Makita, K Takehara, S Saitou, K Satou, K Endou, R Shimoda, Y Matsuzaki, T Matsumoto, K Yuasa.   

Abstract

The therapeutic effect of transcatheter arterial chemoembolization (TAE) performed on 31 patients with primary liver cancer was evaluated using the following procedures: (1) the alpha-fetoprotein (AFP) reduction rates and prognoses were analyzed according to the tumor reduction rates (TR), and (2) the AFP reduction rates and prognoses were also analyzed according to the tumor necrosis rates (TN) estimated by regarding every region with Lipiodol retention as being necrotic. The following results were obtained. The AFP level was 400 ng/ml or higher in 15 patients (48%). Their AFP reduction rates were as favorably high as 65.4%-99.8% (mean, 88.1%), and the AFP level was normalized in 3 patients. The cumulative survival rates after the initial treatment were relatively high, i.e., 78.4% in the 1st year, 58.1% in the 2nd year, and 38.7% in the 3rd year. These results suggested the effectiveness of the TAE treatment undertaken in this study. Regarding the TR, the tumor was reduced in size by 50% or more in only 5 patients (16%), and most patients had a TR of less than 25%. On the other hand, the majority, 25 patients (81%), had a TN ranging between 50% and less than 100%, including 7 who had a TN ranging between 50% and less than 90% and 18 who had a TN ranging between 90% and less than 100%. There was no significant correlation between the AFP reduction rate and the TN or TR. Regarding evaluation of the cumulative survival rates by TR and TN, the 1-year survival rate was lower in patients having a TR of less than 25% than in those having a TR of 25% or more. Patients having a TN of less than 50% showed a poor outcome as compared with those having a TN of 50% or more. Although the TR was found to be less than 50% in a majority of the patients when the therapeutic effect of TAE on the liver cancer was evaluated according to the TR, many of these patients showed a good outcome. Thus, the conventional efficacy evaluation, in which a tumor reduction of 50% or more is considered to be effective, should be reconsidered. On the other hand, the TN was found to be 50% or more in most of the patients, suggesting the necessity of a more detailed classification of TN. In relation to the survival rate, patients having a TN of less than 50% showed a poor outcome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511068     DOI: 10.1007/bf00686669

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Changes in mode of response to chemotherapy for hepatocellular carcinoma induced by transarterial embolization. A case report.

Authors:  N Okazaki; T Yoshida; M Yoshino; S Okada; Y Shimada; N Moriyama; K Takayasu
Journal:  Jpn J Clin Oncol       Date:  1991-02       Impact factor: 3.019

2.  Transcatheter occlusion of abdominal tumors.

Authors:  H M Goldstein; S Wallace; J H Anderson; R L Bree; C Gianturco
Journal:  Radiology       Date:  1976-09       Impact factor: 11.105

3.  Hepatic artery embolization in 120 patients with unresectable hepatoma.

Authors:  R Yamada; M Sato; M Kawabata; H Nakatsuka; K Nakamura; S Takashima
Journal:  Radiology       Date:  1983-08       Impact factor: 11.105

4.  A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma.

Authors:  T Kanematsu; T Furuta; K Takenaka; T Matsumata; Y Yoshida; T Nishizaki; K Hasuo; K Sugimachi
Journal:  Hepatology       Date:  1989-07       Impact factor: 17.425

5.  Selection of therapeutic modalities for hepatocellular carcinoma in patients with multiple hepatic lesions.

Authors:  M Monden; M Sakon; M Gotoh; T Kanai; K Umeshita; K S Wang; M Sakurai; C Kuroda; J Okamura; T Mori
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Clinicopathological study on combination therapy consisting of arterial infusion of lipiodol-dissolved SMANCS and transcatheter arterial embolization for hepatocellular carcinoma.

Authors:  K Jinno; S Moriwaki; M Tanada; T Wada; K Mandai; Y Okada
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.

Authors:  S Kawai; J Okamura; M Ogawa; Y Ohashi; M Tani; J Inoue; Y Kawarada; M Kusano; Y Kubo; C Kuroda
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization.

Authors:  K Tanaka; S Nakamura; K Numata; H Okazaki; O Endo; S Inoue; Y Takamura; M Sugiyama; Y Ohaki
Journal:  Radiology       Date:  1992-11       Impact factor: 11.105

Review 9.  Surgical management of hepatocellular carcinoma.

Authors:  M T Lotze
Journal:  Gastroenterol Clin North Am       Date:  1987-12       Impact factor: 3.806

  9 in total
  1 in total

1.  Fatigue patterns and correlates in male liver cancer patients receiving transcatheter hepatic arterial chemoembolization.

Authors:  Shiow-Ching Shun; Yeur-Hur Lai; Ting-Ting Jing; Chii Jeng; Fa-Yau Lee; Li-Shia Hu; Sue-Yueh Cheng
Journal:  Support Care Cancer       Date:  2004-12-21       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.